RT Journal Article SR Electronic T1 Anaphylaxis to vaccinations: A review of the literature and evaluation of the COVID-19 mRNA vaccinations JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic DO 10.3949/ccjm.88a.ccc075 A1 Margaret M. Kuder A1 David M. Lang A1 Deepa D. Patadia YR 2021 UL http://www.ccjm.org/content/early/2021/03/01/ccjm.88a.ccc075.abstract AB Recent reports of allergic reactions to the Pfizer-BioNTech and the Moderna COVID-19 vaccines have resulted in questions about how and to whom they can be safely administered. Although anaphylaxis was not observed in clinical trials for either vaccine, there have been 21 reported possible cases of anaphylaxis associated with the Pfizer vaccine (11.1 cases per million doses administered) and 10 possible cases associated with the Moderna vaccine (2.5 anaphylaxis cases per million doses administered). The etiology of anaphylaxis in these cases is not fully understood and is an area of active research. The overall incidence of anaphylaxis to COVID-19 mRNA vaccines is very low. By following recommendations from the US Centers for Disease Control and Prevention, an overwhelming majority of the US population can be safely immunized.